On Feb. 28, 2022, the Patent and Trial Appeal Board of the U.S. Patent and Trademark Office (USPTO)…
On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Feb. 22, 2022, Moderna announced a distribution service agreement with Adium Pharma, a leading private Latin American…
On Feb. 16, 2022, Moderna announced that the Therapeutic Goods Administration in Australia had granted provisional registration for…
On Feb. 8, 2022, Moderna announced a new supply agreement with the government of Colombia for 10.8 million…
On Feb. 4, 2022, the Advisory Committee on Immunization Practices (ACIP) issued a standard recommendation for use of…
On Jan. 31, 2022, Moderna announced the U.S. Food and Drug Administration (FDA) had approved the Biologics License…
On Jan. 26, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Dec. 27, 2021, Moderna announced that the Swiss Federal Government had exercised its option to purchase an…
On Dec. 27, 2021, Moderna announced a revised supply agreement with the government of South Korea for 20…
On Dec. 20, 2021, Moderna announced preliminary neutralizing antibody data against the Omicron variant following the Company’s booster…
On Dec. 13, 2021, Moderna announced an agreement with the Australian Government to build a state-of-the-art messenger RNA…
On Dec. 10, 2021, Moderna announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to…
On Dec. 2, 2021, National Resilience and Harvard University announed they had established a five-year research and development…
On Dec. 1, 2021, Moderna announced a revised supply agreement with the UK government for up to 60…
On Nov. 19, 2021, the U.S. Food and Drug Administration (FDA) announced that it had extended the emergency…
On Nov. 16, 2021, an agreement was announced that enabled the European Union and European Economic Area countries…
On Nov. 15, 2021, Moderna confirmed that Health Canada had authorized the use of a booster dose of…
On Nov. 9, 2021, Moderna announced that it has submitted for a variation to the conditional marketing authorization…
On Oct. 31, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had notified the Company…
On Oct. 26, 2021, Moderna announced a new Memorandum of Understanding (MoU) to make up to 110 million…
On Oct. 26, 2021, Moderna announced that Swissmedic had authorized a booster dose of Spikevax, the Company’s vaccine…
On Oct. 25, 2021, Moderna announced positive interim data from the Phase 2/3 study, called the KidCOVE study,…
On Oct. 25, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
On Oct. 14, 2021, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…
On Oct. 12, 2021, Moderna announced that Gavi, the Vaccine Alliance had exercised its option to purchase an…
On Oct. 7, 2021, Moderna announced it was building a state-of-the-art mRNA facility in Africa with the goal…
On Oct. 6, 2021, Washington University School of Medicine announced the start of a pediatric COVID-19 vaccine clinical…
On Oct. 5, 2021, Moderna announced that the European Medicines Agency (EMA) had authorized a third dose of…
On Sept. 28, 2021, Sanofi announced that it had terminated plans for its own mRNA-based COVID-19 vaccine given…